Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
– Closed registered direct offering for aggregate gross proceeds of US$175 million (the “Registered Direct Offering”) led by a syndicate of prominent biopharmaceutical institutional investors – – On track to report topline data from Phase 2 study evaluating CYB004 for the treatment of Generalized
Cybin Announces Results of Annual Meeting of Shareholders
TORONTO –(BUSINESS WIRE)–Aug. 18, 2025– Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, is pleased